Modulari-T
We teach your immune system to attack and cure cancer
Montreal, Canada · Founded 2021
- Headquarters
- Montreal
- Employees
- 1–10
- Founded
- 2021
- Website
- modularit.bio
- Last Round
- Pre-SeedMay 2023
- Rounds
- 1
About
Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise. Modulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue. Modulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.
Summary
Modulari-T is a Biotech company based in Montreal, Canada, founded in 2021. Its most recent funding was a Pre-Seed round in May 2023. Investors include Y Combinator Continuity Fund, Metaplanet and Pioneer Fund.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2023
Investors
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...